Table 5. Multivariate Cox regression analysis in BRAF-mutant melanoma patients treated with vemurafenib.

Parameters	Categories	P-value	HR	95%CI	P-value	HR	95%CI
antiPeg11 expression	high vs low	0.5702	1.43	0.41–4.98	0.4458	0.54	0.11–2.62
antiPeg11 expression	high vs medium	0.0008	7.14	2.26–22.57	0.0131	4.97	1.40–17.66
MEG3 expression	high vs low	0.0071	4.67	3.82–12.75	0.0270	4.21	1.18–15.04
MEG3 expression	high vs medium	0.0001	14.09	3.78–52.51	<0.0001	121.09	17.64–831.43
Sox2ot expression	high vs low	0.0008	9.49	2.54–35.39	0.0001	24.44	5.11–116.97
Sox2ot expression	high vs medium	0.1035	2.41	0.84–6.92	0.0056	6.49	1.73–24.40
Zeb2NAT expression	high vs low	0.0209	0.34	0.03–0.71	0.0025	0.32	0.17–0.68
Zeb2NAT expression	high vs medium	0.0168	0.31	0.13–0.81	0.0441	0.30	0.24–0.74
IGF2AS expression	high vs low				0.0480	3.89	1.99–16.31
IGF2AS expression	high vs medium				0.0118	5.34	1.45–19.69

HR: hazard ratio; CI: confidence interval.